Spanish authorities issued a positive recommendation for national reimbursement of Hemgenix gene therapy for eligible ...

LEXINGTON, Mass. and AMSTERDAM, Oct. 15, 2024 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, ...

LEXINGTON, Mass. and AMSTERDAM, Oct. 15, 2024 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing ...

The approval of Hympavzi makes it the first treatment for both hemophilia A and B to be administered through a pre-filled pen ...

The approval of Hympavzi Friday was a dose of good news for Pfizer, which is dealing with research setbacks and a challenge from an activist investor.

Columnist Alliah Czarielle clears up some common misconceptions about what happens when people with hemophilia have minor cuts or abrasions.

Pfizer's Hympavzi receives FDA approval as the first anti-TFPI therapy for hemophilia A and B. This subcutaneous, once-weekly ...

A new study has punctured a longstanding assumption about the source of the most common type of DNA mutation seen in the genome--one that contributes to many genetic diseases, including cancer.

Pfizer Inc. has won regulatory approval for its hympavzi drug as a treatment for hemophilia A or B without inhibitors - making it the first antitissue-factor pathway inhibitor to be allowed for the ...

Researchers from the Yong Loo Lin School of Medicine, National University of Singapore (NUS Medicine) are working on a ...

Gene Park is a reporter for The Washington Post, covering video games and gaming culture. He joined The Post in 2015 as audience editor, and is a former reporter in the West Coast and Pacific region.

Wendy Fry had just celebrated her first Christmas with her first child, 8-month-old Penny, when she woke the next day to another first: Her daughter having her first seizure. "I have never felt ...